CTLA4 and renal cell carcinoma: Treatment with anti-PD-1, anti-CTLA-4, or interferon alpha-2b was given to patients diagnosed with metastatic or unresectable melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), or neuroendocrine tumors (NET) (2, 16).